Little data exist on the effects of performance status (PS) on the oncological outcomes of patients with prostate cancer (PCa). To determine the efficacy of systemic therapies in patients with worse PS who are treated for high-risk nonmetastatic prostate cancer, metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic/nonmetastatic castration-resistant prostate cancer (nmCRPC), a team of researchers performed a meta-analysis to study several randomized, controlled trials (RCTs) to determine a correlation. ...